Kinexum is a strategic advisory firm providing guidance on regulatory, clinical, CMC and other translational matters for life science product development. From its original expertise in the development of small molecules for diabetes and other metabolic and endocrinal diseases, the firm now advises in multiple additional therapeutic areas (including GI, cardiovascular, oncology and neurology) and modalities (including small and large molecules, cell, gene and tissue therapies, medical devices, digital health tech and nutritionals). We specialize in complex negotiations with and submissions to FDA and other regulatory authorities. Kinexum also aims to contribute to the translation arts and global health, including through promotion of the Metabesity congress and movement to advance prevention of chronic non-communicable diseases of aging and extension of healthy life span. For more information, please visit www.kinexum.com.

Engaged in start up/founding activity in life sciences/healthcare space; advisor to boards and management teams, faculty inventors

Regenerative medicine device company developing the first plant (soy) protein-based skin substitute wound dressing, to replace products made from human and animal sources, to disrupt the multibillion dollar global wound care market.We have animal data showing about 1/3 less scarring and actual recovery of hair follicles and sweat glands, compared to control wounds.We project unit costs less than 1/10 that of currently marketed products, by switching to a plant source and electrospinning (a well-characterized manufacturing process borrowed from the textile industry).Switching to a plant source has 2 game changing consequences. First, several billion people around the globe lack practical access to skin substitutes due to cost and cultural or religious sensitivities to sources such as cadavers, embryonic materials, cows or pigs. Second, in the U.S., a 2014 CMS reimbursement rule bundled and capped product, provider and facility fees for skin substitutes, and cut reimbursement by up to 60%. We have the opportunity to afford access to a life- and limb-saving, culturally sensitive skin substitute at disruptive prices to many millions more patients in the U.S. and around the globe.This technology platform was invented by Peter Lelkes, currently Director of the Temple University Institute of Regenerative Medicine and Engineering. We expect to file for 510(k) clearance within 12 months of closing the next external financing round.

Emerging medtech with expertise in design and development of smart catheter-based devices targeting the blood clot, neurotrauma and intracranial therapeutics delivery markets.

Member of Board, Audit and Nominating and Governance Committees for Bulletin Board listed company developing an ex vivo 'liver dialysis' cartridge

B round CNS company based in Strasbourg, France working on therapeutics for Parkinson's, Duchenne Muscular Dystrophy, etc. and a GPCR drug discovery engine

Life sciences/healthcare start up activities and advisory services

NASDAQ-listed CNS company in Baltimore with approved drug GLIADEL wafer for brain cancer and programs targeting CNS diseases such as Parkinson's

Legal management in ICN Pharmaceuticals Group, including VP, General Counsel & Secretary of quasi-public R&D subsidiary Viratek, and Deputy General Counsel of public international pharmaceutical subsidiary SPI Pharmaceuticals

North American holding company for Australian billionaire Kerry Packer, with interests in environmental remediation, printing and publication, oil & gas leases and real estate and other assets

Corporate legal practice focused on transactional and securities practice, including London office 1983-1985